Free Webinar: Illegal Diversion of Pharmaceuticals
Tuesday, May 14, 2013
11:00 AM - 12:00 PM EDT
To Register go to
As part of its ongoing educational webinar series designed to further best practices for supply chain security, Rx-360 members will address the topic of illegally diverted pharmaceuticals. Illegal diversion is a nebulous issue with grave consequences: a complex combination requiring well thought-out and proven mitigation strategies. This webinar will contextualize the causes and impact of illegal diversion with case studies specific to this issue. Successful mitigation strategies for illegal diversion within the global pharmaceutical supply chain will be highlighted.
Webinar content is derived from the recently released Illegal Diversion of Pharmaceuticalswhitepaper, authored by Rx-360 members from Merck & Co, Amgen, Astra Zeneca, Bristol-Myers Squibb, Genentech, Takeda, Biogen Idec and Johnson & Johnson.
Please click hereto register for a free educational webinar on Illegal Diversion of Pharmaceuticals on May 14, 2013
More information regarding the topics covered in the Rx-360 Illegal Diversion of Pharmaceuticals whitepaper, by clicking here
Illegally diverted pharmaceuticals can have a potentially serious patient safety impact, as they have not passed through a controlled and regulated supply chain. By their nature all cases of illegally diverted product have at some point come into contact with the authorized supply chain; therefore, pharmaceutical manufacturers and distributors are well positioned to potentially have a significant impact on this aspect of illegal trade. This paper collates the expertise and experience of a number of organizations and aims to describe some of the principle causes and consequences of illegal diversion as well as practical mitigation strategies that can be adopted.
The phenomenon of illegal diversion is driven primarily by arbitrage opportunities created by pricing differentials. Many of these price differences have complex origins that have their foundation in regulations and legislation in particular markets. This paper does not seek to address the subject of pharmaceutical pricing; however, it is important to recognize these price differentials and the role they play in illegal diversion.
Illegal diversion is an issue that can occur within individual markets and between national markets; however, this discussion will focus on illegal diversion that occurs between national markets. This particular risk is rapidly increasing due to the growth of complex and interconnected global commerce. The goal of this paper is to provide a compendium of information regarding illegal diversion: an overview of the supply chain and marketplace vulnerabilities contributing to illegal diversion, the impact of this problem and illegal diversion mitigation strategies that have been successfully deployed by pharmaceutical manufacturers.
Please clicking here to access the full text of the Illegal Diversion of Pharmaceuticals whitepaper.
Rx-360 was formed in 2009 to support an industry-wide commitment to ensuring patient safety by enhancing quality and authenticity throughout the supply chain. The mission of the organization is timely in light of growing attacks and threats to an increasingly complex and global supply chain. Millions of people around the world are treated every day with the vital medicines that pharmaceutical and biotechnology companies provide. Management of the pharmaceutical supply chain has become one of the top public health concerns with respect to consumer safety. The globalization of distribution for both drug components and finished products has introduced many complications that Rx-360 is positioned to help resolve. To learn more about Rx-360, go to the website at www.Rx-360.org.
Please share this e-mail with your colleagues. If you are not a registered user on the Rx-360 web site, register for the website for free at www.Rx-360.org
Rx-360 | An International Supply Chain Organization - Washington D.C.